Nootropics Index - Save on smarter supplements
Nootropics>Isolated phytochemicals & plant compounds>CBD / Cannabidiol
Isolated phytochemicals & plant compounds

CBD / Cannabidiol

Cannabidiol

CBD is cannabidiol, a cannabis compound distinct from THC. A small insomnia trial found little advantage for most sleep outcomes and no cognitive improvement. Compare verified CBD content, not hemp-oil weight; liver safety, medicines and local rules matter.

Isolated CompoundLimited Human EvidencePopulation Specific EvidenceSedation RiskLiver CautionMedication Interaction RiskLegal Caution
Updated October 2026/6 min read/8 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
Extra caution

Who should avoid this or get expert review first

This is not a recommendation to use. These groups should treat the profile as a reason to slow down and verify safety, rules, and personal context.

  • Groups outside the safety assessment5Avoid unsupervised CBD use during pregnancy or breastfeeding, below age 25, or while taking medicines. EFSA could not establish safety for these groups; this does not replace specialist-prescribed treatment decisions.
01

What is it?

What the sleep study actually found

1

Thirty adults with primary insomnia received CBD or placebo. Insomnia severity and self-reported sleep latency, efficiency and night waking did not differ. Some secondary wellbeing and objective sleep-efficiency results favored CBD. The small sample and short follow-up limit confidence.

Calm does not mean sharper cognition

2

A second report from the same participants found neither improvement nor worsening on cognitive testing. Subjective calmness improved, but this is not an independent trial or proof of enhanced focus. Drowsiness warnings should not be mistaken for demonstrated cognitive impairment in this study.

02

Names, aliases and forms

Common NameCannabidiol
AbbreviationCBD
03

Potential effects and evidence map

Grade C for nonprescription sleep, calm and cognitive claims: one small insomnia trial produced mostly null sleep results and no cognitive improvement. Subjective calmness signals from that same cohort need replication; prescription evidence does not establish retail nootropic benefit.

Effect domainMagnitudeGrade
Calm / relaxation2
CumulativeConfidence: Low

Subjective calmness improved in a small insomnia cohort; a reliable general relaxation benefit is not established.

Note Subjective secondary outcomes, not an objective performance gain.

1/5
C
Sleep quality1
CumulativeConfidence: Low

Most sleep outcomes were similar to placebo; one objective sleep-efficiency signal needs replication.

Note Small exploratory insomnia study with mostly negative sleep outcomes.

1/5
C
04

Typical dosages and timing

Insomnia pilot1150 mg/night

The insomnia pilot used sublingual CBD 60 minutes before bed during a two-week dosing phase. This protocol is not an established effective or safe daily amount for general use. No universal nootropic dose follows from it.

EFSA, February 202650.0275 mg/kg/day

EFSA set a provisional level of 0.0275 mg/kg/day, approximately 2 mg/day for a 70 kg adult. It applies only to at least 98% pure CBD without nanoparticles, a safe production process and excluded genotoxicity (potential to damage genetic material). This precautionary assessment is not an efficacy dose or blanket product approval.

05

Timing & effect horizon

Effect horizonCumulative
Cumulative
Study window1Cumulative
2 weeks
Study length is not onset1

The two-week study window does not establish when relaxation begins, how long a benefit lasts, or a useful cycling schedule. Sublingual trial findings cannot be assumed to apply equally to every swallowed oil or gummy.

06

Safety, side effects and risk profile

Dose changes the safety picture4
The base low-risk rating concerns short-term oral CBD in otherwise healthy adults, excluding THC mixtures and sedative combinations. Low rather than minimal reflects potentially meaningful loss of alertness, not legal status or evidence gaps. It is not a safe-intake guarantee; lower-dose harm rates remain uncertain.
Sedation / impairment4
Confidence: Medium

CBD can reduce alertness. Do not drive or operate machinery while drowsy.

Note Risk depends on dose and formulation; consumer-dose incidence is not established.

2/5
B
Interaction risk4
Confidence: High

Medication effects can change with CBD. Alcohol and sedatives can increase drowsiness.

Note This targeted interaction caution is not added to the healthy-adult base rating.

3/5
B
Liver / kidney caution3
Confidence: High

Clinically important liver-enzyme elevations occurred in a healthy-adult trial at several-hundred-milligram daily doses.

Note Dose-specific findings are detailed below; the measured rate must not be transferred to lower doses.

3/5
B
Legal / regulatory risk6
Confidence: High

As of 2026-10-12, U.S. federal and EU food rules differ; retail availability is not evidence of authorization.

Note Legal status is separate from pharmacological risk.

2/5
A
Liver findings in healthy adults3

At 5 mg/kg/day (250-550 mg/day) for 28 days, 8 CBD participants (5.6%) had liver enzymes above three times the upper limit of normal, versus none on placebo; 7 met withdrawal criteria for potential liver injury. There were no clinical liver symptoms or significant liver-function changes, and enzymes normalized after stopping. These results do not quantify risk at lower doses. Feeling well did not exclude the laboratory changes.

Tolerability2

Dry mouth was more frequent with CBD in the insomnia cohort. Its small size cannot establish uncommon adverse-event rates.

07

Interactions and cautions

Medicines, alcohol and alertness4

Discuss CBD with a pharmacist or clinician before combining it with medicines. Avoid alcohol or sedative stacking; effects can be additive. Liver disease is a separate reason for clinical review.

08

Legal and regulatory status

United States: product category matters6

As of 2026-10-12, FDA continues to exclude CBD from the federal dietary-supplement definition. Hemp status alone does not authorize a food or supplement, and state rules can differ. This is a U.S. regulatory position, not a global prohibition.

United States: limited 2026 enforcement discretion7

As of 2026-10-12, FDA has announced a narrow non-enforcement position under specified drug provisions for qualifying oral hemp-CBD products supplied through physician-directed Medicare programs. Its April 2026 memo imposes manufacturing, labeling, contamination and child-marketing conditions. This is not general retail supplement approval.

European Union: safety opinions are specific8

As of 2026-10-12, EU novel-food requirements remain relevant. EFSA published a September 2026 safety opinion on a particular synthetic CBD formulation in medium-chain triglyceride (MCT) oil at 2 mg/day for adults over 25, excluding pregnancy and lactation; medicated users were outside established safety. That opinion is not an authorization of all CBD products. Check the actual product and destination rules.

09

How it compares

CBD oil is not hemp seed oil6

CBD identifies a cannabinoid. Hemp seed oil is a food oil and does not naturally supply substantial CBD; trace contamination is different from a stated CBD dose. A large hemp-oil number on the front label is not a cannabidiol amount.

10

Practical buying and quality notes

  • Look for the actual CBD amount, measured THC content and a matching batch analysis covering potency and contaminants. Isolate and mixed-cannabinoid extracts are not interchangeable exposures. A laboratory certificate helps assess the contents; it does not prove efficacy or regulatory approval.4
  • For label comparison only: 600 mg CBD in 30 mL equals 20 mg CBD/mL. Divide the bottle price by 6 for cost per 100 mg CBD. Neither figure is a suggested serving. Compare products with comparable cannabinoid composition, not simply equal oil volume; shipping and testing quality still matter.
11

FAQ

Does CBD produce a THC-like high?

6

CBD is distinct from intoxicating THC, but a product sold as CBD can contain other cannabinoids. Do not equate absence of a THC-like high with absence of drowsiness or impairment.

What CBD dosage is supported for sleep?

1

There is no established general sleep dose. The pilot protocol above mostly failed to outperform placebo; a research amount should not be copied as a serving recommendation.

How long does CBD last, and should it be cycled?

2

The cited repeated-dose trial cannot establish a single-dose benefit duration or a cycling schedule. Its study window is a measurement period, not a recommended on/off cycle.

12

References

  1. Narayan AJ et al. Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial. J Clin Sleep Med. 2024;20:753-763.
  2. Narayan AJ et al. Nightly cannabidiol and daytime neurocognitive performance in primary insomnia. Psychopharmacology. 2025;242:297-308.
  3. FDA. CDER investigators address the safety of CBD in a randomized trial. Accessed 2026-10-12.
  4. FDA. What you need to know about products containing cannabis or cannabis-derived compounds, including CBD. Accessed 2026-10-12.
  5. EFSA. Provisional safe level for cannabidiol as a novel food. 9 February 2026.
  6. FDA. Regulation of cannabis and cannabis-derived products, including cannabidiol: questions 9 and 12. Accessed 2026-10-12.
  7. FDA. Hemp-derived cannabidiol products in medical research models. 1 April 2026.
  8. EFSA NDA Panel. Safety of synthetic cannabidiol as a novel food. EFSA Journal. 2026;24:e10154.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.